Risk of myocardial infarction in Canadian patients with psoriasis: A retrospective cohort study

Journal of Cutaneous Medicine and Surgery

Volumn 17, Issue 6, 2013, Pages 398-403

  Levesque, Annie ^a   Lachaine, Jean ^a   Bissonnette, Robert ^a  

^a INNOVADERM RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN; USTEKINUMAB;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; RETROSPECTIVE STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CONFIDENCE INTERVAL; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROCEDURES; RISK; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY; YOUNG ADULT; METHODOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PSORIASIS; QUEBEC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84891682181     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2013.13052     Document Type: Article

References (12)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912, doi:10.1056/NEJMra041320.
2. Ahlehoff O, Gislason GH, Lindhardsen J, et al. Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. J Intern Med 2011;270:237-44, doi:10.1111/j.1365-2796.2011.02368. x.
3. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41, doi:10.1001/jama.296.14.1735.
4. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009;145:700-3, doi:10.1001/archdermatol.2009.94.
5. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-6, doi:10.1093/eurheartj/ ehp567.
6. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009;129:2411-8, doi:10.1038/jid.2009.112.
7. Maradit-Kremers H, Dierkhising RA, Crowson CS, et al. Risk and predictors of cardiovascular disease in psoriasis: a population-based study. Int J Dermatol 2013;52:32-40, doi:10.1111/j.1365-4632.2011.05430.x.
8. Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012;148:1244-50, doi:10.1001/archdermatol.2012.2502.
9. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011;165:1066-73, doi:10.1111/j.1365-2133.2011.10525.x.
10. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8.
11. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82, doi:10.1136/ard.2010.129916.
12. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12, doi:10.1002/art.22809.